Compare TNET & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | HRMY |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2000 | 2020 |
| Metric | TNET | HRMY |
|---|---|---|
| Price | $47.58 | $34.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $65.80 | $44.11 |
| AVG Volume (30 Days) | 360.2K | ★ 709.3K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | ★ 1.90 | 0.55 |
| Revenue | ★ $5,010,000,000.00 | $868,453,000.00 |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | $3.30 | $12.88 |
| P/E Ratio | ★ $25.17 | $64.00 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $33.67 | $25.52 |
| 52 Week High | $77.61 | $40.87 |
| Indicator | TNET | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 62.32 |
| Support Level | $34.47 | $25.92 |
| Resistance Level | $49.50 | $34.99 |
| Average True Range (ATR) | 1.94 | 1.10 |
| MACD | 0.13 | 0.39 |
| Stochastic Oscillator | 78.87 | 75.30 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.